The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
Prescription Drugs: Advertising, Out-of-Pocket Costs, and Patient Safety from the Perspective of Doctors and Pharmacists This document highlights additional findings from separate surveys of pharmacists and physicians related to their views and experiences on a wide range of health care issues. Issue Brief (.pdf)
These toplines provide the complete results from a comprehensive survey of seniors on their understanding of and views toward the Medicare drug benefit. The survey of 802 seniors was conducted in late October 2005, prior to the start of the benefit's open enrollment period, which runs from Nov. 15, 2005 to May 15, 2006. The survey was conducted and analyzed by researchers at the Kaiser Family Foundation and the Harvard School of Public Health. It…
These toplines provide the results of a 2006 national survey of pharmacists on their views and experiences related to the new Medicare drug benefit. Topline (.pdf)
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.
The Medicare Part D program provides an outpatient prescription drug benefit to more than 50 million older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone prescription drug plans (PDPs) to supplement traditional Medicare and Medicare Advantage prescription drug plans (MA-PDs) that include drug coverage and other Medicare-covered benefits. This brief analyzes Medicare Part D enrollment and costs in 2025 and trends over time, based on data from the…
Poll Finds 9% Say a Family Member or Close Friend Died of an Overdose; 27% Say Either They or Someone Close to Them Has Been Addicted On the ACA This Month, 45 Percent View the Law Unfavorably and 38 Percent View It Favorably With prescription painkiller abuse garnering more attention from the media and policymakers, the latest Kaiser Family Foundation Health Tracking Poll finds most Americans have a personal connection to the issue. In total,…
In his latest column for The Wall Street Journal's Think Tank, Drew Altman uses new polling to explore why painkiller abuse and addiction is rising as a health issue among state and federal policymakers. All previous columns by Drew Altman are available online.
This issue brief provides an overview of the Medicare Part D marketplace in 2023 and key trends over time, focusing primarily on stand-alone Medicare drug plans, including plan availability, premiums, and cost sharing. The brief also describes the prescription drug provisions in the Inflation Reduction Act of 2022 that affect the Medicare Part D marketplace beginning in 2023
In a few short weeks, Medicare will undergo big changes that will have a major impact on nearly 4 million African American seniors and younger people with permanent disabilities who rely on Medicare for their health coverage. More than four in ten African Americans with Medicare lack coverage for their prescription drugs for at least part of the year. Many others will need to make decisions about their existing coverage and the new Medicare benefit.…
As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
© 2026 KFF